{
    "clinical_study": {
        "@rank": "73796", 
        "arm_group": [
            {
                "arm_group_label": "Regadenoson central - peripheral", 
                "arm_group_type": "Active Comparator", 
                "description": "First bolus regadenoson administered central, second bolus administered peripheral"
            }, 
            {
                "arm_group_label": "Regadenoson peripheral - central", 
                "arm_group_type": "Active Comparator", 
                "description": "First bolus regadenoson administered peripheral, second bolus administered central"
            }, 
            {
                "arm_group_label": "Regadenoson central - central", 
                "arm_group_type": "Active Comparator", 
                "description": "First bolus regadenoson administered central, second bolus administered central"
            }, 
            {
                "arm_group_label": "Regadenoson peripheral - peripheral", 
                "arm_group_type": "Active Comparator", 
                "description": "First bolus regadenoson administered peripheral, second bolus administered peripheral"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of the study is to test the accuracy of Regadenoson to induce maximal and steady\n      state hyperemia as compared to central venous infusion of adenosine for assessing fractional\n      flow reserve. (adenosine is considered to be the gold standard)and to investigate the time\n      intervals of maximum hyperemia induced by centrally and peripherally administered\n      Regadenoson."
        }, 
        "brief_title": "Regadenoson and Adenosine", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "Coronary Artery Disease", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 18-80 years\n\n          -  Scheduled for invasive measurement of FFR for diagnostic and interventional purposes\n             in proximal or mid segments of a coronary artery\n\n        Exclusion Criteria:\n\n          -  Severe aortic valve stenosis\n\n          -  History of severe COPD\n\n          -  Syncope or bradycardia (less than 50 beats/min)\n\n          -  Known conduction disturbances (2nd-3rd degree heart-block, sick sinus without\n             pacemaker or long QT-syndrome)\n\n          -  Severe hypotension (RR <90 mmHg)\n\n          -  Patients in whom no access to the coronary circulation can be obtained by the femoral\n             artery or in whom femoral access was problematic\n\n          -  Coronary anatomy not suitable for FFR measurement (extremely tortuous or calcified\n             coronary vessels)\n\n          -  Previous coronary bypass surgery\n\n          -  Recent ST elevation myocardial infarction (<5 days)\n\n          -  Recent non-ST elevation myocardial infarction (<5 days) if the peak CK is >1000 IU\n\n          -  Inability to provide informed consent\n\n          -  Pregnancy\n\n          -  Use of methylxanthines (in the last 12 hours)\n\n          -  Use of Dipyridamol (in the last 48 hours)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01809743", 
            "org_study_id": "NL42049.060.12"
        }, 
        "intervention": [
            {
                "arm_group_label": "Regadenoson central - central", 
                "description": "To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).", 
                "intervention_name": "Regadenoson central -central", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Regadenoson peripheral - peripheral", 
                "description": "To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).", 
                "intervention_name": "Regadenoson peripheral - peripheral", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Regadenoson central - peripheral", 
                "description": "To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).", 
                "intervention_name": "Regadenoson central - peripheral", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Regadenoson peripheral - central", 
                "description": "To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).", 
                "intervention_name": "Regadenoson peripheral - central", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Regadenoson central - peripheral", 
                    "Regadenoson peripheral - central", 
                    "Regadenoson central - central", 
                    "Regadenoson peripheral - peripheral"
                ], 
                "description": "Fractional flow reserve is measured by inducing hyperaemia using central adenosine infusion.", 
                "intervention_name": "Adenosine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Adenosine", 
                "Regadenoson"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Coronary artery disease", 
            "Regadenoson", 
            "Adenosine", 
            "Maximal hyperemia", 
            "Fractional flow reserve", 
            "FFR"
        ], 
        "lastchanged_date": "November 11, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Eindhoven", 
                    "country": "Netherlands", 
                    "state": "Noord-Brabant", 
                    "zip": "5623 EJ"
                }, 
                "name": "Catharina Hospital"
            }
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "4", 
        "official_title": "Comparison of Regadenoson (Rapiscan) and Central Intravenous Adenosine for Measurement of Fractional Flow Reserve", 
        "overall_official": [
            {
                "affiliation": "Catharina Hospital Eindhoven", 
                "last_name": "Nico H.J. Pijls, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Catharina Ziekenhuis Eindhoven", 
                "last_name": "Lokien X van Nunen, MD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Netherlands: Medical Ethics Review Committee (METC)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the gold standard).", 
            "measure": "the accuracy of Regadenoson to induce maximal and steady state hyperemia", 
            "safety_issue": "No", 
            "time_frame": "participants will be followed up during hospital stay, an expected average of 1 day"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01809743"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Catharina Ziekenhuis Eindhoven", 
            "investigator_full_name": "Lokien van Nunen", 
            "investigator_title": "MD", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "description": "To investigate the time intervals of maximum hyperemia induced by centrally and peripherally administered Regadenoson.", 
            "measure": "time intervals of maximum hyperemia", 
            "safety_issue": "No", 
            "time_frame": "participants will be followed up during hospital stay, an expected average of 1 day"
        }, 
        "source": "Catharina Ziekenhuis Eindhoven", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Lokien van Nunen", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}